News Breaks |
|
|
| February 8, 2013 |
| 07:07 EDT |  | SHPG | Shire announces initiation of Phase 3 study of ABH001
Shire announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa, a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US. |
|
|
News For SHPG From The Last 14 Days Check below for free stories on SHPG the last two weeks. |
|
|
| May 20, 2013 |
| 10:03 EDT | | SHPG | Shire advances after report renews takeover speculation
 Subscribe for More Information |
|
| 07:27 EDT |  | SHPG | American Psychiatric Association to host annual meeting
Subscribe for More Information |
|
| 07:01 EDT | | SHPG | Sangamo BioSciences announces positive data for Vivo Protein platform
Sangamo BioSciences (SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform to produce therapeutically relevant levels of Factor VIII in a mouse model. Sangamo has partnered with Shire (SHPG) to develop ZFP Therapeutics for both hemophilia A and B using this approach. |
|
| 06:30 EDT |  | SHPG | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT |  | SHPG | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 14, 2013 |
| 07:24 EDT | | SHPG | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 10, 2013 |
| 10:00 EDT |  | SHPG | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 05:42 EDT | | SHPG | Shire downgraded to Neutral from Overweight at JPMorgan
|
|
| May 9, 2013 |
| 12:24 EDT | | SHPG | Shire unit wins patent trial against Watson regarding LIALDA
Shire (SHPG), announces that its subsidiary, Shire Development, has prevailed in its litigation against Watson Pharmaceuticals, Watson Laboratories-Florida, Watson Pharma. and Watson Laboratories in connection with their Abbreviated New Drug Application for a generic version of Shire's LIALDA delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Following a five day bench trial in the Southern District of Florida, Judge Middlebrooks issued a ruling upholding the validity of the patent covering LIALDA, US Patent No. 6,773,720, and holding that the proposed ANDA formulation infringes the claims of that patent. Accordingly, Judge Middlebrooks confirmed that Shire is entitled to an injunction, which he will issue separately, which prohibits the FDA from approving the ANDA formulation until the expiration of the '720 patent. |
|
| 10:17 EDT | | SHPG | Shire trades higher in London amid takeover chatter, Guardian says
Subscribe for More Information |
| |
|
|
|
|
